Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-administration of Influsplit Tetra with Pneumovax 23 in at-risk adults aged 50 years and older
2014-001118-24Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2014
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Influsplit and 23-valent pneumococcal polysaccharide vaccine in influenza and pneumococcal disease (2 arms), sponsored by GSK. Primary endpoint: Humoral immune response to each influenza strain. Started Jul 2014; status: completed.
02
Drugs
Influsplit23-valent pneumococcal polysaccharide vaccine
03
Conditions
influenzapneumococcal disease
Beyond the preview
Go deeper on 2014-001118-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001118-24.